https://www.fiercebiotech.com/biotech/biontech-pays-autolus-250m-...

https://www.fiercebiotech.com/biotech/biontech-pays-autolus-250m-manufacturing-car-t-expertise-wide-ranging-collab

$250 million upfront collaboration.

https://investors.biontech.de/news-releases/news-release-details/biontech-presents-positive-preliminary-phase-12-data-first-class
https://www.biontech.com/int/en/home/pipeline-and-products/pipeline.html#bnt211-solid-tumors

BNT211 aimed at solid tumors. They've completed phase 1/2 and looking promising for testicular cancer.

Pharma companies sitting on $171 billion of cash reserves, oncology tipped to be a major focus.

Our Phase 1b and early CHM 2101 data towards the end of the year should put us right in the firing line. Something to keep in mind when people keep taking about our cash reserves.

Can't hurt Chimeric having a world class team of cell therapy pioneers when pharma are doing their assessments